Prokarium Closes $21M Series B Financing Round and Strengthens Board
Prokarium, a privately-held biotechnology company developing novel immunotherapies and vaccines based on its engineered microbial platform, today announced the closing of a Series B investment round of $21M led by Korea Investment Partners (KIP). In addition to KIP, the UK government’s Future Fund (FF), Flerie Invest and Riyadh Valley Company (RVC) also participated in the financing round.
“We are very pleased with this strong financial support and with the global networks our investors bring,” said Ted Fjallman, PhD, CEO of Prokarium. “The funds will support the development efforts of our microbial immunotherapy for the treatment of non-muscle invasive bladder cancer, which we plan to advance to the clinic by 2022, as well as the expansion of our pipeline across multiple solid tumours. This financing, together with our recently announced partnership with the Wellcome Trust for funding our clinical studies of Entervax, positions Prokarium well to realize the potential of our microbial immunotherapy platform.”
“KIP is delighted to lead this financing of Prokarium and to continue to invest in their team and platform” said Sangwoo Lee, Managing Director, KIP. “Prokarium’s approach of developing microbial immunotherapy that stimulates innate immunity and modulates the tumour microenvironment is very exciting and has the potential to transform cancer treatment across the world.”
In conjunction with the financing, Hyam Levitsky, MD, will join Prokarium’s Board of Directors. Hy brings over 30 years of internal medicine, oncology and immunology research experience and currently serves as the President of Research and Development at Century Therapeutics. Prior to Century, he served as the Executive Vice President and Chief Scientific Officer at Juno Therapeutics and Head of Cancer Immunology Experimental Medicine at Roche.
“I am excited to join Prokarium’s Board and to provide my scientific expertise to develop novel microbial immunotherapies” said Hyam Levitsky. “Prokarium’s bacterial strains have the potential to be potent activators of multiple innate immune pathways, harnessing intrinsic microbial properties combined with modulatory effects from cutting-edge engineering to initiate and drive a patient’s anti-tumor responses. This harbours the potential to perform both as a monotherapy or in combination with other immunotherapies.”
Prokarium also strengthens its executive team with the promotion of Kristen Albright, PharmD, to Chief Operating Officer, Livija Deban, PhD, to Vice President of Research, and the appointment of Peter McGowan, FCCA, as Chief Financial Officer.
"I am very pleased to announce these well-deserved appointments on Prokarium's executive team," said Steve Chatfield, PhD, Chairman of Prokarium. "It is critical that we have the optimal organizational structure in place to drive the continued advancement of our pipeline and the success of our company."
- Ends -
Prokarium is a clinical-stage biopharmaceutical company focused on developing microbial cancer immunotherapies. Using the company’s leading-edge technology platform, Prokarium’s mission is to use its expertise in engineering biology and immunology to improve the lives of patients with solid tumours, with its lead oncology program expected to enter the clinic in 2022. The Company is also leveraging its platform, in conjunction with the Wellcome Trust, for the phase 1 and phase 2 clinical evaluation of a combination vaccine against typhoid and paratyphoid. Prokarium is headquartered in London, UK. For more information please visit www.prokarium.com.
About Korea Investment Partners
Korea Investment Partners (KIP) is South Korea’s leading venture capital and private equity firm with over 30 years of experience investing in bold and innovative entrepreneurs who want to change the world. KIP manages over 20 venture and private equity funds with over $2.6 billion AUM. The company operates globally from its Seoul headquarters office with other locations in Shanghai, Beijing, and Sunnyvale. Notable successful life science exits include Elastagen to Allergan, Auris Health to Johnson and Johnson, as well as multiple IPOs such as ABL Bio [Kosdaq: A298380], Helixmith [Kosdaq: 084990], Qurient [Kosdaq: 115180], i-Sense [Kosdaq: 099190], HLB [Kosdaq: 028300], and PCL [Kosdaq: 241820].
About Non-Muscle Invasive Bladder Cancer (NMIBC)
Around 550,000 cases of bladder cancer occur every year with approximately 70% of tumours diagnosed as non-muscle invasive bladder cancer. NMIBC remains a very challenging cancer to treat with high rates of recurrence and progression associated with approved therapies. The first-line treatment is Bacillus Calmette-Guérin (BCG), an attenuated tuberculosis (TB) vaccine that is instilled directly into the bladder requiring up to 27 instillations. Intravesical therapies remain the most promising route of administration; however, very little innovation has been invested to replace and improve upon BCG since its approval by the FDA in 1990. Currently there remains a severe global shortage of BCG, which leaves limited treatment options for newly diagnosed NMIBC patients.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ipsen Receives FDA Fast Track Designation for Investigational Irinotecan Liposome Injection (ONIVYDE ® ) as a Second-Line Monotherapy Treatment for Small Cell Lung Cancer (SCLC)30.11.2020 22:58:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for irinotecan liposome injection (ONIVYDE®) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need. ONIVYDE® is currently approved in the United States and in Europe in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. ONIVYDE® is not indicated as a single agent for the treatment of patients with metastatic adenocarcinoma of the pancreas. An ongoing Phase III randomized study (RESILIENT; NCT03088813) trial is being conducted to assess the efficacy and safety of investigational irinotecan liposome injection (ONIVYDE®) as a monotherapy for SCLC study patients who have progressed on or a
Amblin Partners Announces New Multi-Year Film Distribution Partnership With Universal Filmed Entertainment Group30.11.2020 22:00:00 CET | Press release
Amblin Partners today announced a new multi-year film distribution partnership with Universal Filmed Entertainment Group, as well as a series of new agreements that chart a clear course for the next phase of growth for one of the world’s leading independent film and television studios. The new deals were announced this morning by Steven Spielberg, Amblin’s Founder and Chairman. Remarked Spielberg: “My decades-long relationship with Universal truly transcends any single business deal, and to once again renew our corporate vows reaffirms that Universal is Amblin’s home. In addition to Universal, we are blessed to continue forward with a global family of partners, including Alibaba, eOne and Reliance, each of which has supported us for many years and enabled our storytelling to touch the lives of millions of moviegoers around the world. I would also like to extend my deepest gratitude to my dear friends Jeff Skoll and David Linde for an incredible run as formal partners; and my congratula
Little Cinema Taps Verimatrix To Secure Hollywood’s Virtual Premiere Events30.11.2020 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that New York-based Little Cinema deployed Verimatrix Watermarking and Multi-DRM technologies for its virtual premieres and previews. A groundbreaking digital studio, Little Cinema has partnered with Netflix, ABC, CBS, HBO Max, and Warner Media to produce state-of-the-art virtual premiere events for an industry that used to rely solely on in-person debuts. To fulfill the enhanced protection requirements for this high-value early-release content, Little Cinema looked to Verimatrix and its Secure Cloud. These innovative and highly-interactive virtual streaming events have made waves in Hollywood, earning the studio recognition in BBC News, Vogue, Variety, Vanity Fair, The Hollywood Reporter, and more. “Verimatrix supplies us with the needed anti-piracy protections and overall peace of mind that Hollywood studios demand when switching to virtual events
Emory University to Host a Live Webcast With His Holiness the Dalai Lama30.11.2020 16:39:00 CET | Press release
The Center for Contemplative Science and Compassion-Based Ethics at Emory University will host a live webinar with His Holiness the Dalai Lama on Tuesday, December 8, 2020. A discussion titled “The Necessity of Compassion for the Survival of Humanity” will feature the Dalai Lama in conversation with Melani A. Walton, co-founder of the Rob and Melani Walton Foundation, and Dr. Sanjay Gupta, chief medical correspondent for CNN. (For speaker photos click here.) The webcast begins at 10:30pm ET on Dec. 8, 2020 (Dec. 9 @ 9:00am India Standard Time) and will be simulcast in 14 languages. It is FREE of charge and open to anyone who’d like to participate. Advance registration is encouraged at https://compassionshift.emory.edu. “With so many urgent concerns impacting our world, the time is right to start a global conversation about the importance of compassion,” said Lobsang Tenzin Negi, executive director of Emory University’s Center for Contemplative Science and Compassion-Based Ethics. “For
Flexjet Advances European Expansion with Delivery of First Embraer Praetor 60030.11.2020 15:03:00 CET | Press release
Flexjet Ltd., offering travelers access to the world’s most luxurious fleet of private jets, accepted delivery of the first Praetor 600 aircraft in its European-based fleet, marking a significant milestone in the expansion of the company’s global business. Flexjet is the only shared-ownership/fractional provider of the Praetor 600, part of a US$1.4 billion order for Embraer Executive Jets, a division of Embraer S.A. (NYSE: ERJ; BM&FBOVESPA: EMBR3), that was announced in October 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005564/en/ Flexjet Embraer Praetor 600 super midsized aircraft part of the European-based Flexjet fleet. (Photo: Business Wire) European Managing Director Marine Eugène leads the team headquartered at Flexjet House in the Mayfair neighbourhood in the west end of London. In addition, Flexjet has opened facilities including a European Tactical Control Centre in the United Kingdom to coordinate f
Kymeta™ Announces Commercial Availability of its Next-Generation Antenna, Terminal, and Services Making Mobile Global30.11.2020 15:00:00 CET | Press release
Kymeta (www.kymetacorp.com)—the communications company making mobile global—announced that the Kymeta™ u8 and Kymeta Connect™ are available for government and commercial purchase after November 30, 2020, unlocking the potential of broadband satellite connectivity and cellular networks to satisfy the overwhelming demand for communications on the move. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005022/en/ Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, first responders, and commercial customers. Kymeta’s products and services have been field deployed for three years and the demand for the Kymeta u8 presales has already exceeded expectations. With the introduction of the Kymeta u8, the company has meaningfully increased antenna throughput and significantly reduced the total cost of ownership. Kymeta’s new products and services offer a bre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom